Integrins as therapeutic targets
作者： Simon L. Goodman , Martin Picard
DOI: 10.1016/J.TIPS.2012.04.002
关键词:
摘要: … A small-molecule LFA-1 inhibitor (SAR-1118) is entering Phase III trials in ophthalmology to treat dry… In this short review we cannot consider the many compounds suggested to influence …
elsevier.com
sci-hub.se 参考文章(68)
Arthur Kaser, Herbert Tilg, Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease. Current opinion in investigational drugs. ,vol. 11, pp. 1295- 1304 ,(2010)
Oliver Kisker, Integrins: Targets for Anti-Angiogenic Therapy Tumor Angiogenesis. pp. 761- 777 ,(2008) , 10.1007/978-3-540-33177-3_42
R.M. Scarborough, M.A. Naughton, W. Teng, J.W. Rose, D.R. Phillips, L. Nannizzi, A. Arfsten, A.M. Campbell, I.F. Charo, Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. Journal of Biological Chemistry. ,vol. 268, pp. 1066- 1073 ,(1993) , 10.1016/S0021-9258(18)54042-4
Richard O. Hynes, Integrins: Bidirectional, Allosteric Signaling Machines Cell. ,vol. 110, pp. 673- 687 ,(2002) , 10.1016/S0092-8674(02)00971-6
Eugenio Pucci, Giorgio Giuliani, Alessandra Solari, Silvana Simi, Silvia Minozzi, Carlo Di Pietrantonj, Ian Galea, Natalizumab for relapsing remitting multiple sclerosis Cochrane Database of Systematic Reviews. ,(2011) , 10.1002/14651858.CD007621.PUB2
S O'Day, , A Pavlick, C Loquai, D Lawson, R Gutzmer, J Richards, D Schadendorf, J A Thompson, R Gonzalez, U Trefzer, P Mohr, C Ottensmeier, D Chao, B Zhong, C J de Boer, C Uhlar, D Marshall, M E Gore, Z Lang, W Hait, P Ho, A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma British Journal of Cancer. ,vol. 105, pp. 346- 352 ,(2011) , 10.1038/BJC.2011.183
Eduardo J. Villablanca, Barbara Cassani, Ulrich H. von Andrian, J. Rodrigo Mora, Blocking lymphocyte localization to the gastrointestinal mucosa as a therapeutic strategy for inflammatory bowel diseases. Gastroenterology. ,vol. 140, pp. 1776- 1784 ,(2011) , 10.1053/J.GASTRO.2011.02.015
Dermot Cox, Marian Brennan, Niamh Moran, Integrins as therapeutic targets: lessons and opportunities Nature Reviews Drug Discovery. ,vol. 9, pp. 804- 820 ,(2010) , 10.1038/NRD3266
Payaningal R Somanath, Nikolay L Malinin, Tatiana V Byzova, None, Cooperation between integrin ανβ3 and VEGFR2 in angiogenesis Angiogenesis. ,vol. 12, pp. 177- 185 ,(2009) , 10.1007/S10456-009-9141-9
P S Hodkinson, T Elliott, W S Wong, R C Rintoul, A C Mackinnon, C Haslett, T Sethi, ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death & Differentiation. ,vol. 13, pp. 1776- 1788 ,(2006) , 10.1038/SJ.CDD.4401849